Disease breathalyser firm Owlstone appoints ‘serial entrepreneur’ to board
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
With genetic analysis and diagnostic tests now available via mail order, how will this trend towards the proactive consumer impact the evolution of health management?
Angle hopes Parsortix will be first approved cell-based liquid biopsy.
Breath Biopsy will be tested in its ability to detect several cancers earlier than traditional methods.
Circulating tumour cell test could help select drug therapy.
Partner Fund Management agrees to drop lawsuits.